The use of monoamineoxidase inhibitors in the treatment of depression is increasing again in Australia. This paper outlines changes in prescribing, the problems associated with monoamineoxidase (MA 0) inhibitors and how they relate to the practice of anaesthesia.
chianti (McGilchrist 1975) , have a low tyramine content and are therefore unlikely to cause severe interactions if taken in small amounts but their effects may be enhanced (Sargant 1975) .
The recognition of a variety of interactions associated with MAO inhibitors led, in the late 1960's, to an upsurge of interest in drug interactions and their mechanisms (Brown and T\BLE .. 1 ('{iOIl' 0/ IIIOI/OUnlilll' oxidll\l' 1970 , Stockley 1974 ) and the evolution of many charts and references on drug interactions of all types since that time. MAO is an important enzyme at a variety of sites in the body for breaking down monoamines such as noradrenaline, tyramine, dopamine and 5-hydroxytryptamine (Wulfson and Politzer 1962) . The known and probable mechanisms of action of MAO inhibitors are outlined in Table 1 .
The inhibitors of MAO in the gut remove the protective mechanism by which active amines such as tyramine are destroyed as they are absorbed. These amines behave as indirectly acting sympathomimetic amines releasing noradrenaline and causing hypertension.
Some MAO inhibitors such as tranylcypromine and phenelzinc are structurally similar to amphetamine ( Figure 2 ) and thus have indirect sympathomimetic activity which may cause hypertension.
A decrease in breakdown of monoamines at adrenergic nerve endings can result in accumulation of incrcased amount of noradrenaline (Kopin and Axelrod 1963), dopamine and other precursors so that the amount of noradrenaline subsequently released may be increased. The excess quantities of the precursor amines of noradrenaline may later act as false transmitters, producing a weaker effect on the receptors than noradrenaline. This may account for the orthostatic hypotension sometimes seen in patients on MAO inhibitors and the use of pargyline as a hypotensive drug. The reduced breakdown of central nervous system amines, such as 5-hydroxytryptamine and noradrenaline, produces the antidepressent effect in psychiatry.
It is also possible that inhibition of microsomal cnzymes in the liver may result in increased toxicity of drugs which are detoxified by monoamineoxidase or the production of breakdown products which are themselves toxic (Taylor 1962 , Witton 1962 tranquilizers, antihypertensives, insulin and sulphonylureas. The action of these drugs are increased, sometimes profoundly. Certain drugs commonly used by anaesthetists interact as follows:
1. Analgesics a. Pethidine:-Unconsciousness, hypotension, hyperpyrexia and death have been reported (Papp and Benaim 1958 , Pells-Cocks and Passmore Rowe 1962 , Reed and Jones 1962 , Palmer 1960 , Shee 1960 , Denton, Borrell and Edwards 1962 . The mechanisms suggested have been decreased breakdown of pethidine, the interference with breakdown leading to the production of toxic compounds but possibly the most likely mechanism in relation to hyperpyrexia is due to increased cerebral 5-hydroxytryptamine (5HT) content caused by MAO inhibitors and potentiated by pethidine which blocks neuronal uptake of 5HT. A critical level of this monoamine in the brain may be necessary for a drug interaction to take place (Penn and Rogers 1971 ) . The cause of hypertension which occasionally occurs may be excessive endogenous catecholamine release in response to hypercarbia and hypotension.
A drop in blood pressure and tachycardia usually develop after pethidine 5-10 mg intramuscularly in susceptible patients. Churchill Davidson (1965) suggested a more elaborate test in which the dose is doubled hourly for four doses while recording the pulse, blood pressure and respiratory rate.
b. Morphine:-Although some interactions similar to pethidine may occur they seem to be much less likely (Vickers 1965, Penn and Rogers 1971) and there is a report of a patient on phenelzine who had been given morphine without adverse effect but died following subsequent doses of pethidine (Palmer 1960 ). If it is proposed to give morphine, a test dose of 1 mg intramuscularly should be given and the patient observed for changes in pulse, blood pressure and respiration. c. Pentazocine:-Experimental studies using mice pretreated with iproniazid and tranylcypromine have shown that the acute toxicity is increased (Rogers and Thornton 1969) but subsequent studies in rabbits treated with pargyline indicate that pentazocine is safer than pethidine or morphine (Penn and Rogers 1971) . A test dose of 5 mg should be given if it is proposed to use this drug.
2. Thiopentone:-Barbiturates may have their action prolonged and enhanced by MAO inhibitors (Stockley 1974) . Thiopentone has been used frequently in patients on MAO inhibitors with no ill effects, but hypotension and hypertension has been reported in a patient on tranylcypromine following thiopentone (J enkins and Graves 1965) .
3. Suxamethonium:-Patients on phenelzine have been found to have Iow pseudocholinesterase levels which rose on cessation of the drug. One patient had prolonged apnoea (1 hour) following suxamethonium (Bodley, Halmax, Potts 1969) .
4. Vasoconstrictors:-These drugs cause hypertension in patients on MAO inhibitors and it is wise to avoid them although the British Dental Journal has stated that "the Iow concentration of adrenaline given with local anaesthetics in dentistry present no special hazards to patients on MAO inhibitors" (Brit. Dental J. 1970) . It may be that a small volume of a low concentration of a direct acting sympathomimetic amine such as adrenaline or noradrenaline is less hazardous than drugs with indirect sympathomimetic activity which cause hypertension.
5. Inhalation anaesthetics:-Sleeping time may be prolonged. Experimental studies have shown that MAO inhibitors prevent the breakdown of 5-hydroxytryptamine and both MAO inhibitors and 5HT prolong sleep time with general anaesthetics (Wulfson and Politzer 1962) .
6. Other drugs with sympathetic stimulating actions and those acted on by MAO should be avoided .during anaesthesia.
The major problems an anaesthetist is likely to encounter are cardiovascular instability, coma and hyperpyrexia. Severe hypertension can be treated with sodium nitroprusside or an alpha blocker such as phentolamine (5 mg intravenously and repeated if necessary) (Goldberg 1964) . Conventional antihypertensives should be avoided as drugs such as reserpine may aggravate the problem. Tachyarrhythmias requiring treatment can be managed with beta blockers as the problem is due to sympathetic overactivity.
Chlorpromazine has been used successfully in a number of patients following severe interactions with pethidine. It will lower blood pressure, counteract hyperthermia and quieten hyperactive patients.
The anaesthetist shouLd be aware of the hazards of interactions with mono amine oxidase inhibitors. Faced with a patient on MAO inhibitors the choice is between (1) postponing the operation, stopping the drugs and allowing time for the resynthesis of adequate amounts of monoamine oxidase which takes 2 to 3 weeks or (2) proceeding with caution. The difficulty is that monoamine oxidase inhibitors cause interactions by many mechanisms and there is still uncertainty about how an individual patient will respond to an anaesthetic, especially if the blood pressure is unstable preoperatively (Witton 1962) . If the operation cannot be postponed care should be taken to give a test dose of analgesic preoperatively as described. Pethi.dine should be avoided altogether in favour of morphine or pentazocine. Other drugs with amine groups should be injected slowly while the patient's response is assessed.
